Understanding OUR Cytokine-Based Immunotherapy Candidates Our Determination extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, specifically for cancers where procedure options remain limited. Use the links below to learn far more about our portfolio of cytokine-based immunotherapy candidates. Explore Our Pipeline https://financefeeds.com/iexec-unveils-2025-roadmap-to-expand-rlc-utility-and-advance-confidential-ai/